Intratumoral ( i.t. ) injections of an adenovirus encoding the human interleukin -2 ( IL -2 ) under the control of the RSV ( Ad -pRSV -IL -2 ) or CMV ( Ad -pCMV -IL -2 ) promoter were performed in established mastocytoma P815 tumors in B6D2 mice. Both early and long -term survival were found increased in mice treated with Ad -pCMV -IL -2 as compared with those obtained with Ad -pRSV -IL -2: tumor regression was observed in 30 ± 50% of mice for the former and 5 ± 15% for the latter. Difference in efficacy between the two vectors was directly correlated to the amount of IL -2 produced i.t. between 24 and 48 hours postinjection, which reached 10 ± 20 ng / tumor for Ad -pCMV -IL -2 and 0.3 ± 0.5 ng / tumor for Ad -pRSV -IL -2. In both cases, expression in the tumor was clearly detectable for a period of 7 ± 10 days postinjection. Serum IL -2 was not detectable in mice treated with Ad -pRSV -IL -2, whereas expression peaked at a total of 1 ± 2 ng at 24 hours but declined very rapidly in the Ad -pCMV -IL -2 ± treated group. Constant production of IL -2 inside the tumor was necessary for successful therapy because i.t. injections of recombinant IL -2 at levels up to 1 g for five consecutive days did not lead to antitumoral activity. Evidence of induced systemic immunity following Ad -pCMV -IL -2 injections was obtained from rechallenge experiments in which tumor -free mice after treatment rejected a subsequent contralateral injection of a lethal dose of P815 tumor cells and from the observation that regression of nontreated tumors occurred in animals bearing bilateral tumors that were treated i.t. in a single tumor with Ad -pCMV -IL -2. P815 -specific cytotoxic T lymphocytes ( CTL ) were found specifically in spleen cells from cured mice or rechallenged mice but not in control mice. Interestingly, limiting dilution analysis of anti -P815 CTL precursor ( CTLp ) frequency revealed a significant increase in mice cured of their tumor as compared to that obtained in naive mice or control mice treated or not with Ad -IL -2 but whose tumor was growing. In vivo depletion of T -cell subsets, as well as natural killer cells at the time of i.t. injections with Ad -pCMV -IL -2, demonstrated that both CD8 + T cells and natural killer cells, but not CD4 + T cells, were required for successful therapy. Finally, mice preimmunized with Ad -null viruses were severely compromised in their capacity to eradicate established P815 tumors after Ad -pCMV -IL -2 therapy, at least when neutralizing antibody titers reached a critical level. Cancer Gene Therapy ( 2001 ) 8, 321 ± 332
I
nterleukin -2 ( IL-2) is a potent activator of T cells, natural killer ( NK ) cells, and lymphokine-activated killer cells. 1, 2 Systemic delivery of recombinant IL -2 to patients has been approved for the treatment of renal cell carcinoma and has also shown some clinical efficacy for the treatment of other malignancies including malignant melanoma. 3 ± 5 However, clinical efficacy is limited by the large doses of IL -2 required for effective treatment, which are associated with several side toxic effects and the short half -life of the protein. 6 In attempts to overcome these limitations, tumor cells transduced ex vivo by either plasmid DNA or viral vectors expressing the IL -2 gene have been employed as effective tumor vaccines, which protect animals from simultaneous or subsequent tumor challenge. 7 ± 12 For clinical application, however, ex vivo transfection of human tumor cells remains a laborious, time -consuming, expensive procedure and this approach might not ever offer a useful return on the investment. 13 An alternative approach to cancer immunotherapy involves the direct delivery of therapeutic genes into established tumors. Candidate genes and strategies involve the use of suicide genes to kill tumor cells directly; genes encoding immunogenic tumoral antigens or cytokines to induce immune -mediated destruction or genes such as p53, caspase -7 or Bax which will turn the aberrant biology of tumor cells against themselves. 14 ± 19 In animal models, in vivo gene therapy with the IL-2 cDNA has been reported using either adenoviral vectors or plasmid -based delivery systems. 20 ± 25 These studies, performed with different animal models, showed that following intratumoral ( i.t. ) transfer of the IL -2 cDNA, it is possible to induce a systemic immunity, mainly mediated by CD8 + cells where animals showing a complete response develop protective immunity to re -challenge with parental tumor cells. Whether this cytolytic activity reflects a de novo clonal T-cell response or if local IL -2 acts as an activator of an existing population of T cells remains to be demonstrated. Moreover, the contribution of NK cells to the antitumoral activities generated after IL-2 gene delivery was rarely studied.
In this communication, we employed as a model the wellcharacterized weakly immunogenic P815 mastocytoma cell line for our studies. Five tumor antigens expressed by P815 have been identified according to recognition by cytotoxic T lymphocyte (CTL ) clones, and the gene encoding two of these antigens, P1A, has been cloned and characterized. 26, 27 The genomic sequence of P1A in P815 cells is identical to that in DBA /2 kidney cells, indicating that it is a normal gene that is abnormally expressed. It is expressed by several mastocytoma cell lines, but not in normal tissue except for testis and placenta, and in this way mirrors the expression of the human tumor genes of the MAGE family. 28, 29 We show that following i.t. administration of an Ad -IL -2 vector in established P815 tumor, the amount of IL -2 produced inside the tumor is a critical parameter for successful eradication of established tumor cells. Both CD8 + T cells and NK activity were found to be essential for successful eradication of established P815 tumor. Limiting dilution analysis of CTLp in mice cured of their tumor after Ad -IL-2 therapy revealed an increase in specific CTLp, characteristic of an in vivo immunization process against P815 antigens. Finally, induced pre -existing immunity against adenovirus did change the outcome of i.t. injection of Ad -IL -2, at least when neutralizing antiadenoviral antibodies reached a critical threshold.
MATERIALS AND METHODS

Adenoviral vectors
All viral genomes were constructed as infectious plasmids by homologous recombination in Escherichia coli as described. 30 The vector AdTG6624 contains the cDNA for human IL -2 under the control of the human cytomegalovirus immediate -early enhancer /promoter region and the simian virus 40 late polyadenylation sequences in an adenovirus type 5 backbone, which contains a deletion in E1 from nucleotide (nt ) 455 to 3328 and in E3 from nt 28593 to 30470, according to the nucleotide numbering of Chroboczek et al. 31 In this background ( ÁE1ÁE3 ), the vector AdTG6401 without transgene served as internal negative control. The vector AdTG6214 contains the cDNA for human IL -2 under the control of the chicken Rous Sarcoma Virus 3
H LTR / promoter and the rabbit B -Globin polyadenylation sequences in an adenovirus type 5 backbone, which contains a further deletion in the E4 region as compared with AdTG6624. 32 The E1 /E3 ± and E1 /E3 /E4 ± deleted vectors were grown on 293 cells and 293-E4ORF6 in seven cells, respectively. 32, 33 Virus propagation, purification, and titration of infectious units ( virus concentration expressed as infectious units /mL ) by indirect immunofluorescence of the DNA binding protein were as described. 32 
Cell lines
The P815 mastocytoma cell line of DBA /2 origin was obtained from the European Collection of Animal Cell Culture ( Salisbury, UK ) . 34 The NK -sensitive, Moloney virus ± induced YAC -1 thymic lymphoma of A / Sn origin and the B16F0 melanoma cell lines were obtained from the American Type Culture Collection (Rockville, MD ) . The tumor cell lines were grown in complete Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum.
Mice
Female B6D2 mice were purchased from IFFA Credo (Lyon, France ) and maintained in our own specific pathogen-free animal facility. Mice were 6 ±8 weeks of age at the onset of each experiment.
In vivo treatment of tumor -bearing mice
Mice were inoculated subcutaneously into the right flank with a dose of 3Â10 5 cells in a volume of 0.1 mL of phosphate -buffered saline (PBS ). Approximately 10 days following tumor cell inoculation, mice showing palpable tumor ( minimal volume of 14 mm 3 ) were randomized between the different experimental groups. The adenoviral vector was diluted at the desired concentration in Tris ( 10 mM ) , pH = 8, MgCl 2 (1 mM ), and injected i.t. Mice were scored for tumor growth in three dimensions using calipers weekly and tumor volume was calculated assuming a spheroid. Values for tumor volumes are reported as average SEM. The animals were sacrificed when the longest diameter of the tumor exceeded 25 mm.
For contralateral experiments, animals were injected simultaneously in each flank with 3Â10 5 cells in the right hind flank and with half or a quarter of this dose in the left flank in order to avoid rapid death of the mouse. Tumorbearing animals were injected i.t. in the right flank exclusively as described above.
In vivo expression of cytokines P815 tumors growing in B6D2 mice were injected with 5Â10 8 infectious units of the desired vector. At least five mice were sacrificed at each individual time point: the tumor was extracted, weighed, and mechanically disrupted in 1 mL of PBS with protease inhibitors ( Complete Protease Inhibitor Cocktail Tablets; Boehringer Mannheim ). The suspension was centrifuged ( 12,000Âg, 2 minutes, 48C) and the supernatant was frozen at À 208C. Samples were next assayed for human IL -2 using the Quantikine Human Immunoassay from R&D system. Results were expressed as picograms of IL -2 per milligram of tumor (mean SEM ) .
Cytotoxicity assays
For CTL assays by 51 Cr release, spleens were harvested and disrupted using the top of a syringe. The lymphocytes were counted and diluted at 5Â10 6 cells/mL and set in coculture with mitomycin C ±treated P815 tumor cells at a ratio of 50:1 for a period of 5± 7 days at 378C in 5% CO 2 . Following coculture, standard 51 Cr release assays were carried out in 96 -well V-bottomed microtiter plates. P815 tumor cells were labeled with 51 Cr ( 100 Ci /2Â10 6 cells). Effector:-target ratio ranging from 100 to 1.25 were prepared in a final volume of 200 L and incubated for 4 hours at 378C. The background and maximum release were determined by adding the target cells in 100 L of medium alone and 100 L of 1 N hydrochloric acid, respectively. The percentage of specific lysis was evaluated according to the formula: [ (cpm experimental À cpm background) / ( cpm maximum À cpm background ) ] Â100. For NK activities, 51 Cr -labeled, NK -susceptible target, YAC cells ( 5Â10 3 cells ) and effector spleen cells were mixed in V-bottomed microtiter plates at effector:target ratio ranging from 100 to 1.25. After 4 hours of incubation at 378C, cell -free supernatant was collected, and radioactivity was measured in a gamma counter. P815 tumor cells, which are NK -resistant target, were used as control. The percentage of specific lysis was evaluated as described above for CTL assays.
Neutralizing antibody assay
Serial 2-fold dilutions of serum were prepared in PBS with magnesium and calcium containing 1.8Â10 4 infectious units of Ad -lacZ and incubated at room temperature for 1 hour. An aliquot of the serum /Ad -lacZ mixture was added to the wells of a 96-well plate seeded 18 hours earlier with 4Â10 4 293 cells /well. After incubation for 1 hour at 378C, 100 L of fresh Dulbecco's modified Eagle's medium was added. After 24 hours of incubation, the medium was removed and the cells were washed once with PBS. A solution containing the fluorescent -gal substrate MUG ( 4-methyllumbelliferyl --D -galactoside ) at 0.17 mg /mL diluted in Z buffer (Na 2 HPO 4 60 mM, NaH 2 PO 4 40 mM, KCl 100 mM, MgSO 4 1 mM, and -mercaptoethanol 500 mM ) with 0.5% Triton X -100 was added to each well ( 0.1 mL ). After incubation for 30 minutes at 378C, the fluorescence at 340 nm was recorded using the Victor system ( Wallach) . The titer of neutralizing antibodies was expressed as the inverse of the dilution required to produce 50% reduction in lacZ activity as measured by fluorescence at 340 nm. Results are expressed as the average titer and the standard error of the mean (SEM ) for a defined group of mice.
In vivo immunological studies
Monoclonal antibodies anti -CD4 (GK1.5 ) and anti -CD8 ( 53-6 -72 ) were produced as ascites in nude mice and subsequently purified using protein A column. Monoclonal antibodies were injected intraperitoneally ( i.p. ) (150 g/ injection ) at days À 3, 0, and +4 relative to the first i.t. injection of adenovirus vector. For NK depletion, 20 L of anti -asialo -G M1 antibody ( Wako ) was injected 3 days before and the same day as the first adenoviral i.t. injection. This dose did not deplete CD8 + T cells in B6D2 mice as reported recently. 35 Flow cytometric analysis of splenocytes from animals treated with this protocol revealed that > 95% of the targeted population remained depleted for at least 15 days. On day 10 after P815 tumor cell inoculation, palpable established tumors were injected with 5Â10 8 infectious units Ad -pCMV -IL -2 for three consecutive days or with increasing doses of rIL -2 (Proleukin, Chiron) as indicated for five consecutive days. In the second experiment, rIL -2 was mixed with Adeno -null vector AdTG6401 during the first three injections in order to give the same viral load as in the group treated with Ad -pCMV -IL -2 alone.
Cancer Gene Therapy, Vol 8, No 5, 2001 Limiting dilution analysis Spleen cells were seeded at eight different concentrations ( from 6.4Â10 5 to 5Â10 3 cells /well ) and 24 replicates were set up for each concentration. Spleen cells were stimulated for 6 days with mitomycin C ±treated P815 cells and 12.5 ng /mL of IL -2 (Proleukin, Chiron ). Cytolytic activity was determined in the 51 Cr release assay as described above using 5Â10
3 51 Cr -labeled P815 cells. Background wells set up in the absence of responding cells were used to determine the threshold for``positive'' wells at a level of three SD above the mean background. The frequency of CTL precursor ( CTLp ) was estimated using the weighted mean method from the Poisson distribution relationship between the number of responding cells and the logarithm of the percentage of nonresponding cultures using the LDA software (Rovensky P, Rubes J, Beran T ) accompanying the recent book of Lefkovitz and Waldmann. 36 
Statistical analysis
Statistical significance of animal survival was assessed by a log -rank test. The significance between survival curves was defined as a P value of less than .05. Fisher's probability 
RESULTS
In vivo expression of human IL -2 inside P815 tumor as a critical factor for antitumoral activity Two different vectors, AdTG6214 and AdTG6624, containing the human IL -2 gene under the control of the RSV or CMV promoter, respectively, were directly compared for their capacity to control and eradicate established P815 tumors in B6D2 mice after direct i.t. injections of a 5Â10 8 infectious units dose per injection, a value that was found to be optimal in preliminary dose ± responses studies ( data not shown ). Control groups injected either with Tris buffer or Adeno -null vector AdTG6401 did not show any antitumoral activities ( Fig 1 ) . Tumors injected with AdpCMV-IL -2 remained usually stable for about 10 ±15 days and finally 42% (10 /24 ) of the mice was completely cured of their tumor. The percentage of mice whose tumors were reduced in size following Ad -pRSV-IL -2 was less than that observed with Ad -pCMV-IL -2 and led to 17% tumor eradication (Fig 1) . Most of the mice that died early after Ad -pCMV-IL -2 or Ad -pRSV-IL -2 treatment usually had tumors, which were not of great size (average volume $1000 mm 3 ), but rather, after dissection, appeared to have metastatic spread in the liver and presented enlarged spleens contributing presumably to the early death of these mice.
To determine if the difference in antitumoral efficacies brought about by Ad -pCMV-IL-2 and Ad -pRSV-IL -2 vectors could be explained by a difference in IL -2 levels inside the tumor mass, a time course of IL-2 expression following a single i.t. injection of 5Â10 8 infectious units of the vectors was performed over a period of 2 weeks. The level of IL-2 following injection of Ad -pRSV-IL -2 was rather stable between days 1 and 9 after the injection and was found equal to ca. 3 ±5 pg/mg of tumor corresponding to a total amount of IL-2 of approximately 300± 500 pg, the average weight being 100 mg /tumor ( Fig 2 ) . In contrast, for the Ad -pCMV-IL -2 ± treated group, the concentration of IL -2 was close to 100 pg/mg of tumor the day after the injection to give a total amount of IL-2, which was comprised between 10 and 20 ng /tumor. However, IL-2 expression decreased rapidly by day 6 and stabilized around 10 pg IL -2 /mg of tumor for about 10 days ( Fig 2A ) . There was no background detectable when tumors were injected with Tris buffer or Adeno -null vector (not shown ). The IL-2 concentrations that were found in the serum were proportional to the amount produced within the tumor mass, as can be seen in Figure 2B . Assuming a total volume of 1 mL for the blood of the mice, there was a peak of expression in the serum with approximately 1 ng/mL IL -2 for AdpCMV-IL-2± treated mice, which is one order of magnitude below that found inside the tumor, indicating highly localized expression of IL -2 within the tumor mass. Serum IL -2 was not detectable in the group of mice treated with Ad -pRSV-IL -2 ( sensitivity of the assay around 30 pg/ mL ). Mice that underwent complete tumor regression after treatment, and which were challenged with a lethal dose of P815 cells into the opposite flank, remained tumor-free whereas all naive control mice developed a tumor and finally died (not shown ). Moreover, P815 -resistant mice were not protected from a contralateral challenge with the unrelated B16F0 melanoma tumor cell line. Thus, mice in which tumors had regressed following Ad -IL-2 treatment developed a specific long -term immunity against a subsequent tumor challenge.
Due to the difference in efficacy between the two vectors, all the experiments described below in this report were performed with the Ad -pCMV-IL -2 virus.
Comparison of the antitumoral activities of Ad -IL -2 with that of recombinant IL -2
The efficacy of direct i.t. injections of rIL -2 compared to the gene therapy approach with Ad -IL-2 was studied. Recombinant human IL -2 protein was injected for five consecutive days into P815 tumors to mimic more or less the in vivo expression kinetics of IL -2 observed with Ad -pCMV-IL -2 inside P815 tumors (Fig 2A ) . Three concentrations of IL -2 were chosen: 10 ng, which is roughly equivalent to the amount produced per day in P815 tumors injected with 5Â10 8 infectious units of Ad -pCMV-IL -2 ( see above ) and amounts increased by one log, i.e., 100 and 1000 ng. As can be seen from the survival curve shown in Figure 3 , there was a strong increase in survival in the Ad -IL -2 ±treated group with 50% of the mice being cured of their tumor whereas for each dose of rIL -2, there was no detectable antitumoral activity.
In a second experiment, a group of mice was treated i.t. with rIL -2 mixed with Ad -null vector that might trigger inflammatory reactions. As in the first experiment, there was no increase in survival in the group of mice treated with rIL -2 or rIL -2 mixed with Ad -null ( data not shown ). A summary of the percentage of tumor rejection in the various experimental groups is indicated in Table 1 .
Regression of distal untreated tumors
The i.t. delivery of IL-2 within P815 tumor might eventually induce an immune response capable of controlling distal, noninjected P815 tumor. Mice were thus co-injected in both flanks with P815 tumor cells: 3Â10 5 cells in the right flank, which will be injected with the Ad -IL -2 vector, and 0.75Â10 5 or 1.5Â10 5 cells in the left flank. A lower dose of tumor cells in the contralateral side prevents a rapid death of the mice ( data not shown ). In the control group injected with Tris, the volume of both tumors (injected and not injected ) was not reduced. However, in the Ad -IL -2 ± injected group, both tumors (treated and untreated ) were growing at a slower rate compared to the control group, at least during a period of 10 days after the i.t. injections. ( Fig  4A ) . After this period, a fraction ( approximately 50% ) of the mice, whose tumors did not grow in both side, starts to escape immune surveillance in the contralateral site. Finally, a 2-fold reduction in the percentage of tumor rejection was observed in mice bearing two tumors compared to the mice bearing a single tumor. The survival curve of this experiment is shown in Figure 4B . CTL responses are specific of the tumor rejection process in Ad -IL -2 ± treated P815 cells Based on the depletion experiment described above, the presence of specific anti -P815 CTL response in spleen cells of tumor-free mice or tumor-bearing animals was addressed in a standard 51 Cr release assay. In the majority of the cases, both tumor-free mice after Ad -IL -2 therapy and mice that were resistant to a secondary tumor challenge displayed a high degree of specific P815 target cell killing (Table 2) . No above -basal -level specific lysis was detected in such experiments when control target cells like YAC or murine melanoma B16F0 were used. An example of this experiment is shown in Figure 6A . Moreover, none of the mice ( 0/ 13) that were refractory to Ad -IL -2 treatment exhibited any specific P815 CTL lysis ( Table 2 , lane 3 ), indicating that the generation of anti -P815 CTL responses was specific of the rejection process.
To monitor the in vivo induction of the P815-specific cytotoxic response, CTLp was quantified by LDA. The same LDA experiment was used to determined the frequency of CTLp in the spleen of mice bearing growing P815 tumors ( untreated or injected with Tris or Adeno -null vector AdTG6401; Figure 6B ) and mice that rejected their P815 tumor following Ad -IL -2 immunotherapy (Fig 6C ) . The frequency of CTLp in control mice was extremely low ( 3.03Â10 À 7 as average value for three mice) whereas CTLp in tumor-free mice after Ad -IL -2 therapy increased significantly (6.26Â10 À 6 as average value for three mice) , demonstrating efficient immunization against P815 tumor antigens ( P<.01).
Because NK cells can be activated by IL -2, the NK activity in the spleen of mice was assessed using YAC cells as targets. 37 A good NK activity was detectable early, i.e., 1 or 2 days after the Ad -pCMV-IL -2 treatment, in the spleen of mice (Fig 7A ) and this activity subsequently waned (data not shown) . As expected, when used as target in the NK assay, P815 tumor cells were resistant to the NK activity ( Fig 7B ) . The observed NK activity in the spleen might be particularly important in this model because P815 tumor cells, after subcutaneous injections, rapidly migrate in the spleen and in the liver. 38 Whether there are infiltrates of NK cells and /or activated NK cells within P815 tumor is currently under investigation.
High titer antiadenoviral antibodies abolish the antitumoral activities of i.t. administrated Ad -IL -2 vector
To investigate the effect of neutralizing antibodies on the outcome of Ad -IL-2 immunotherapy, mice were immunized intravenously (i.v.) or i.p. with 5Â10 8 infectious units of AdTG6401 vector. Two different routes of administration were chosen because they were known to induce different levels of antibody responses with also qualitative differences. 39 P815 tumor cells were next injected and the tumors were treated i.t. as usual. The survival curves of these different groups are shown in Figure 8 .
The positive control group, which was not preimmunized, gave an expected result, i.e., net increase in survival compared to the Tris -injected group with ultimately 30% of the mice (6 /30 ) cured of their tumor. In contrast, both preimmunized groups showed a strong decrease in longterm survival compared with the nonimmunized group and finally, there was no tumor rejection. The presence of neutralizing antibody responses was assayed in both groups: the titers were close to 2000 in the i.v.-treated group ( 1829 308) whereas there was a 2 -fold decrease in the i.p. -treated group (854 110) . A correlation between the neutralizing antibody titers and the severity of the decrease in the Ad -IL -2 biological effect is thus observed.
These results were in opposition to those published by Bramson et al 40 who immunized mice by the nasal route with a lower dose of vector (10 8 vs. 5Â10 8 infectious units) and found no influence of preimmunization on the in vivo efficacy of an Ad -IL -12 vector in their model (a mouse model of mammary adenocarcinoma) . 40 The neutralizing antibody titers were in the range of 300. Therefore, in order to compare in the same protocol of immunization, the results published by Bramson et al mice were immunized in a second experiment by the nasal route with the same dose as published ( i.e., 10 8 infectious units) and i.v. immunizations with increasing doses of adenovirus were also performed. Both intranasal and i.v. immunizations at the lowest dose slightly decrease the overall long -term survival ( data not shown) . Finally, a small, nonsignificant decrease in tumor rejection frequency occurred as compared to the control, nonimmunized group (Table 3 ) . However, i.v. immunization with 10 8 infectious units and 5Â10 8 infectious units of Adeno -null vector AdTG6401 curtailed severely the longterm survival ( data not shown ), and hence led to a significant decrease in tumor rejection as compared to the control, nonimmunized group ( Table 3) . The in vivo expression of IL -2 inside P815 tumors as shown in Figure  8b was completely abolished in mice preimmunized by the i.v. route at the highest dose ( 5Â10 8 infectious units ) , suggesting that the neutralizing antibodies present in these mice prevent the infection process of P815 tumor cells.
DISCUSSION
The direct delivery of cytokine genes inside tumors in clinical trials continues to increase. 41 This approach of in vivo gene therapy of cancer can be characterized by three key features: (i) a strong concentration of an immunostimulatory molecule inside injected tumors; (ii ) the persistence of the molecule at a concentration for a period of time necessary to trigger a therapeutic response; and ( iii ) a low, nontoxic 8 infectious units of AdTG6401 ( Adeno -null vector ) . The tumors were treated as described in Material and Methods and IL -2 was measured using an ELISA. The IL -2 expression was normalized to the tumor mass as an indication of local``concentration.'' The control group refers to the group of mice that were not preimmunized with Adeno -null. 8 infectious units of Ad -pRSV-IL -2 or Ad -pCMV-IL -2, total expression within the tumor approximates 1 and 10 ng, respectively. The expression of IL-2 was rather constant for 1 week for Ad -pRSV-IL -2 ± infected P815 tumor whereas expression dropped rapidly by day 3 for AdpCMV-IL -2 and then stabilized for a period of 1 week. The antitumoral efficacy of Ad -pCMV-IL -2, as measured by early survival following the onset of adenoviral injection and by the fraction of mice, which ultimately eradicate their tumor, was found to be superior to that obtained with the vector Ad -pRSV-IL-2. This result is most likely the consequence of the observed difference in the maximum amount of IL -2 produced within the tumor. The amount of IL -2 found in the blood was also very different between the two vectors: it is thus possible that the higher amount of IL -2 in the blood of mice treated with Ad -pCMV-IL -2 contributes to the better early survival observed by activating antitumoral activities in organs such as the spleen or the liver, where P815 is known to migrate. 38 In accordance with that hypothesis, a clear NK activity was detected in the spleens of mice that were treated with i.t. injections of Ad -pCMV-IL -2. Conversely, animals that were treated with Ad -pRSV-IL -2 showed no detectable NK activity in the spleen the next day after i.t. injections ( data not shown) . The fact that AdpRSV-IL-2 ( ÁE1ÁE3ÁE4 ) is not isogenic to the vector Ad -pCMV-IL -2 ( ÁE1ÁE3 ) is not likely to explain the difference in efficacy between the two vectors. When injected by the systemic route, (ÁE1ÁE3ÁE4 ) vectors have been indeed found recently to be less inflammatory and less hepatotoxic than their ( ÁE1ÁE3 ) counterparts. 42 Though inflammatory reactions were not studied in our experiment, the addition of Adeno -null vector AdTG6401 ( ÁE1ÁE3 ) to Ad -pRSV-IL -2 did not increase its biological activity as compared to Ad -pRSV-IL -2 alone in our experiments (data not shown ). Thus, the amount of IL -2 produced inside the tumor is most likely the key feature explaining the difference in antitumoral activity between the two vectors.
When equivalent or higher amounts of rIL -2 than that produced inside the P815 tumor cells following Ad -pCMV-IL -2 injection were injected within the tumor for five consecutive days, no antitumor activity was recorded, indicating that the constant delivery of IL-2 within the tumor is likely a key point to this immunotherapeutic strategy.
The fact, that mice that eradicate their primary tumor following Ad -IL -2 immunotherapy were protected from a second tumor challenge and that it was possible to eradicate a fraction of distant nontreated P815 tumors, demonstrates that systemic immunity was induced. The selective depletion of T-cell subsets at the time of Ad -IL -2 treatment indicates that both CD8 + T cells as well as NK cells are the effectors of tumor rejection whereas CD4 + T cells had no negative influence on the antitumor activity induced by Ad -IL -2 treatment. A slight transient improvement of the antitumor response was in fact observed, indicating that CD4 + T cells may be inhibitory toward CD8 + T cells activated following IL -2 or IL -12 therapy. 43 ± 45 Consistent with these observations, the induction of specific anti -P815 CTL responses was associated with the rejection process because control mice or mice whose tumors were growing after Ad -IL -2 therapy did not show any CTL responses. More importantly, limiting dilution analysis of CTLp in mice cured of their tumor showed a significant increase in specific anti -P815 CTLp as compared to control mice, demonstrating in vivo immunization. This conclusion was also shared by Levraud et al 46 and Pannetier et al 47 who characterized tumor infiltrating lymphocyte in regressing P815 tumors using the``Immunoscope'' approach. In contrast to our result, using a quantitative reverse transcriptase ±coupled PCR method to analyze the T-cell receptor variable regions, activation of pre -existing T-cell clones was found in regressing tumors of a derivative of the melanoma B16 model that was treated with a recombinant antibody -IL -2 fusion protein. 48 This discrepancy might be due to the different model used or to the different means of IL -2 administration.
The influence of the presence of neutralizing antibodies against the viral vector before i.t. injections was investigated in our model. As found by Bramson et al 40 in a mouse mammary carcinoma model, immunization by the nasal route ( 10 8 infectious units ) did not diminish the efficacy of the treatment in our model. However, immunization by the i.v. route with the 10 8 and 5Â10 8 doses decreased significantly the antitumoral activity of Ad -IL-2 vector, which was associated for the highest dose with a complete block of IL -2 expression. These results indicate that at least in this model, neutralizing antibody titers above 1000 will preclude gene transfer. In a recent phase I clinical trial performed with a replication -defective Ad -5 carrying a suicide gene that was administered intrapleurally, pretreatment titers of neutralizing antibodies were all inferior to 500 and did not preclude gene transfer. 49 After vector instillation, neutralizing antibodies titers raised significantly ( 4 -to 341 -fold increase in 18 of 20 patients ) . Similar data have been reported in another phase I clinical trial after i.t. Ad -IL-2 administration in metastatic breast cancer and melanoma where persistence of expression was recorded at days 7 and 14 postinjection in 18 of 22 patients (83% ) though preexisting antiadenoviral antibodies were not recorded. 50 Altogether, these data suggest that in humans, previous immunity to adenovirus infection does not preclude prolonged persistence of adenovectors after a single injection into tumors whereas gene transfer could be severely limited during secondary injections of adenoviral vectors. Whether there will be a need of multiple injections for clinical efficacy in humans and whether the increase in antiadenoviral antibodies will limit expression of the candidate gene will have to be assessed in future phases I and II clinical trials that are currently planned.
